[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

SG11201701648UA - Use of cysteamine in treating infections caused by yeasts/moulds - Google Patents

Use of cysteamine in treating infections caused by yeasts/moulds

Info

Publication number
SG11201701648UA
SG11201701648UA SG11201701648UA SG11201701648UA SG11201701648UA SG 11201701648U A SG11201701648U A SG 11201701648UA SG 11201701648U A SG11201701648U A SG 11201701648UA SG 11201701648U A SG11201701648U A SG 11201701648UA SG 11201701648U A SG11201701648U A SG 11201701648UA
Authority
SG
Singapore
Prior art keywords
cysteamine
yeasts
moulds
infections caused
treating infections
Prior art date
Application number
SG11201701648UA
Inventor
Deborah O'neil
Vanessa Duncan
Original Assignee
Novabiotics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novabiotics Ltd filed Critical Novabiotics Ltd
Publication of SG11201701648UA publication Critical patent/SG11201701648UA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/145Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41961,2,4-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • A61K31/497Non-condensed pyrazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SG11201701648UA 2014-09-22 2015-09-21 Use of cysteamine in treating infections caused by yeasts/moulds SG11201701648UA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462053523P 2014-09-22 2014-09-22
GBGB1416727.4A GB201416727D0 (en) 2014-09-22 2014-09-22 Use
PCT/GB2015/052714 WO2016046524A1 (en) 2014-09-22 2015-09-21 Use of cysteamine in treating infections caused by yeasts/moulds

Publications (1)

Publication Number Publication Date
SG11201701648UA true SG11201701648UA (en) 2017-04-27

Family

ID=51869299

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201701648UA SG11201701648UA (en) 2014-09-22 2015-09-21 Use of cysteamine in treating infections caused by yeasts/moulds

Country Status (14)

Country Link
EP (1) EP3197476A1 (en)
JP (1) JP2017532317A (en)
KR (1) KR20170052613A (en)
CN (1) CN106687140A (en)
AU (1) AU2015323566B2 (en)
BR (1) BR112017005272A2 (en)
CA (1) CA2959003A1 (en)
GB (1) GB201416727D0 (en)
MX (1) MX2017003550A (en)
NZ (1) NZ730092A (en)
RU (1) RU2017108196A (en)
SG (1) SG11201701648UA (en)
WO (1) WO2016046524A1 (en)
ZA (1) ZA201701330B (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2770113T3 (en) 2015-07-02 2020-06-30 Horizon Orphan Llc ADO-resistant cysteamine analogues and their uses
JP2020505359A (en) * 2017-01-25 2020-02-20 アデア ファーマシューティカルズ,インコーポレイテッド Cysteamine prodrug
WO2018224813A1 (en) * 2017-06-06 2018-12-13 Novabiotics Limited Use of cysteamine compositions
CA3116637A1 (en) * 2018-10-17 2020-04-23 Novabiotics Limited Dosage regime
CN110551637B (en) * 2019-09-03 2020-11-27 黑龙江省农业科学院植物保护研究所 Echinospora echinocandii from radix astragali root for efficiently inhibiting botrytis cinerea and application thereof
CN110859950B (en) * 2019-11-25 2021-08-10 武汉大学 Pharmaceutical composition for candida albicans echinocandin drug-resistant bacteria and application thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5696164A (en) * 1994-12-22 1997-12-09 Johnson & Johnson Consumer Products, Inc. Antifungal treatment of nails
US6086921A (en) * 1995-04-25 2000-07-11 Wintrop-University Hospital Metal/thiol biocides
ES2613027T3 (en) * 2004-08-18 2017-05-22 Novabiotics Limited Antibacterial peptides
JP2006347989A (en) * 2005-06-20 2006-12-28 Pola Chem Ind Inc Antifungal medicine composition for nail
JP2006347990A (en) * 2005-06-20 2006-12-28 Pola Chem Ind Inc Antifungal medicine composition for nail
GB0905451D0 (en) * 2009-03-31 2009-05-13 Novabiotics Ltd Biofilms
MX2012001766A (en) * 2009-08-13 2012-03-07 Moberg Derma Ab Compositions and methods for treating fungal infection of the nail.
GB201021186D0 (en) * 2010-12-14 2011-01-26 Novabiotics Ltd Composition

Also Published As

Publication number Publication date
RU2017108196A3 (en) 2019-06-19
AU2015323566B2 (en) 2018-03-22
NZ730092A (en) 2018-05-25
WO2016046524A1 (en) 2016-03-31
JP2017532317A (en) 2017-11-02
AU2015323566A1 (en) 2017-04-06
EP3197476A1 (en) 2017-08-02
RU2017108196A (en) 2018-10-24
ZA201701330B (en) 2018-04-25
KR20170052613A (en) 2017-05-12
CN106687140A (en) 2017-05-17
MX2017003550A (en) 2017-07-28
BR112017005272A2 (en) 2017-12-12
CA2959003A1 (en) 2016-03-31
GB201416727D0 (en) 2014-11-05

Similar Documents

Publication Publication Date Title
IL283086A (en) Use of cannabidiol in the treatment of tuberous sclerosis complex
HRP20192119T8 (en) Composition and method for aiding sleep
PL2923823T3 (en) Moulding body and method for its production
SG11201702688UA (en) Methods of treating rsv infections
SG11201609652RA (en) Treatment of polybacterials infections
GB201416006D0 (en) Organotypic skin model
ZA201701330B (en) Use of cysteamine in treating infections caused by yeasts / moulds
GB201416102D0 (en) Impovements In or Relating To Shower Rods
HK1225994A1 (en) Compositions for use in the treatment of allergic conditions
ZA201608607B (en) Novel fluoroquinolones and use thereof to treat bacterial infections
GB201405013D0 (en) Improvements in or relating to manufacture of packaging
IL249152B (en) Botulinum toxin for use in the treatment of paratonia
IL251040A0 (en) Use of cysteamine in treating infections caused by yeasts/moulds
IL249616A0 (en) Methods for treating infections
GB202013077D0 (en) Improvements in and relating to servo valves
PT3160263T (en) Compositions and methods for preventing infections
ZA201801788B (en) Lysobactin for use in the treatment of bovine mastitis
GB201521802D0 (en) Mould treatment
GB201410990D0 (en) General cure to diseases